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A B S T R A C T
Prostaglandin E2 (PGE2) plays a key role in inflammation-associated carcinogenesis. NAD+-dependent 15-hy-
droxyprostaglandin dehydrogenase (15-PGDH) catalyzes the oxidation of the 15(S)-hydroxyl group of PGE2 to
generate 15-keto PGE2. 15-PGDH has been known as a tumor suppressor in various malignancies including colon
cancer. However, the molecular mechanisms underlying the tumor-suppressive function of 15-PGDH remain
largely unresolved. In this study, we found that 15-keto PGE2 upregulated the expression of heme oxygenase-1
(HO-1), a representative antioxidative and anti-inflammatory enzyme, at both transcriptional and translational
levels, in human colon epithelial CCD 841 CoN cells. A redox-sensitive transcription factor, NF-E2-related factor
(Nrf2) plays a critical role in the regulation of HO-1 and other cytoprotective proteins. 15-Keto PGE2 induced
translocation of Nrf2 into the nucleus and antioxidant response element-driven luciferase activity. Furthermore,
the silencing of the Nrf2 gene abolished 15-keto PGE2-induced HO-1 expression in CCD 841 CoN cells. 15-Keto
PGE2 activated AKT signaling, and the pharmacological AKT inhibitor, LY294002 suppressed the 15-keto PGE2-
induced HO-1 expression. 15-Keto PGE2 generates the reactive oxygen species which is suppressed by the general
antioxidant N-acetyl-L-cysteine. N-acetyl-L-cysteine treatment attenuated the 15-keto PGE2-induced phosphor-
ylation of GSK3β, transcriptional activity of Nrf2, and subsequently HO-1 expression. However, 13,14-dihydro-
15-keto PGE2 lacking the α,β-unsaturated carbonyl moiety failed to induce intracellular production of reactive
oxygen species, HO-1 expression and nuclear translocation of Nrf2. In conclusion, 15-keto PGE2 induces HO-1
expression through Nrf2 activation in human colon epithelial cells.
1. Introduction
Inflammatory bowel disease (IBD), such as Crohn's disease and ul-
cerative colitis, has been characterized as sustained chronic in-
flammation of small intestine and colon, which promotes the colorectal
carcinogenesis (CRC). There is a vicious cycle between oxidative stress
and inflammation, and oxidative stress is hence one of the pathogenic
factors of IBD [1]. Overexpression of cyclooxygenase-2 (COX-2) is one
of the hallmarks of IBD [2] and inflammation-associated CRC [3]. As a
consequence of overexpression of COX-2, prostaglandin E2 (PGE2) is
overproduced by the microsomal prostaglandin E synthase from the
substrate, prostaglandin H2, a metabolic product of arachidonic acid
[4].
The intracellular level of PGE2 is regulated not only by COX-2-
catalyzed synthesis but also by further metabolism. 15-hydro-
xyprostaglandin dehydrogenase (15-PGDH) is the NAD+-dependent
enzyme responsible for the oxidation of PGE2 to generate the 15-keto
PGE2. A high level of PGE2 is observed in polyps and carcinoma tissue
of patients [5]. 15-PGDH was found to be down-regulated in the IBD
patients, indicative of the additional mechanism on a high level of PGE2
in these patients [6]. Down-regulation of 15-PGDH is also observed in
colon cancer and other tumors [7–11]. In contrast, the induction of 15-
PGDH expression by some chemopreventive agents has been shown to
suppress CRC [12,13]. For example, synthetic triterpenoids suppress
the colon carcinogenesis induced by azoxymethane plus dextran sulfate
sodium (DSS) through upregulation of 15-PGDH [13]. Therefore, the
induction of 15-PGDH expression is considered as a novel cancer che-
mopreventive strategy [14].
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The anti-carcinogenic and anti-inflammatory effects of 15-PGDH
have been known to be mediated through its catalytic product, 15-keto
PGE2. 15-Keto PGE2 has been shown to protect against experimentally
induced sepsis [15]. It increased the p21 expression via peroxisome
proliferator-activated receptor γ activation, thereby suppressing the
growth of hepatocellular carcinoma [16]. In addition, 15-keto PGE2
induces apoptosis in pancreatic cancer by suppressing the expression of
solute carrier family 7 member 11 and cystathionine γ-lyase which are
associated with generation of glutathione (GSH) [17]. Our recent study
has demonstrated that 15-keto PGE2 directly interacts with Cys259 of
signal transducer and activator of transcription 3 (STAT3), leading to
functional inactivation of this transcription factor [18]. We have also
observed that 15-keto PGE2 inhibits tumor growth in xenograft mice
transplanted with breast cancer cells [18].
The redox-sensitive nuclear factor-erythroid-2-related factor 2
(Nrf2), a member of the basic leucine zipper transcription factors, is the
guardian of redox homeostasis. It plays a pivotal role in cellular defense
against not only oxidative but also inflammatory stress [19]. Nrf2
regulates the expression of antioxidant enzymes and other cytoprotec-
tive proteins to protect the cells against oxidative, electrophilic and
inflammatory stresses [20]. Under the normal physiological condition,
Nrf2 is degraded by its repressor Kelch-like ECH-associated protein 1
(Keap1) through the ubiquitination-proteasome pathway [21]. Under
the oxidative stress, however, the release of Nrf2 from the Keap1 re-
pression renders Nrf2 stabilized [22,23]. Accumulated Nrf2 then
translocates into the nucleus, where it binds to antioxidant/electrophile
response elements (ARE/EpRE) and regulates antioxidant enzymes such
as NAD(P)H:quinone oxidoreductase-1 (NQO1), heme oxygenase-1
(HO-1), thioredoxin (TXN), glutathione S-transferase, glutathione per-
oxidase, superoxide dismutase, glutamate-cysteine ligase, catalase, etc.
[22,23]. Nrf2 is released when it is phosphorylated by a protein kinase
or Keap1 is modified in its cysteine thiol group(s) by reactive oxygen/
nitrogen species or electrophiles. Because of the α,β-unsaturated car-
bonyl moiety 15-keto PGE2 carries, this electrophilic lipid mediator acts
as a Michael reaction acceptor, capable of reacting with diverse sig-
naling molecules, such as Keap1, harboring nucleophilic cysteine re-
sidues.
In this study, we have attempted to determine whether 15-keto
PGE2 can activate Nrf2 signaling in normal colon epithelial cells.
2. Methods
2.1. Chemicals and reagents
15-Keto PGE2 and 13,14-dihydro-15-keto PGE2 were purchased
from Cayman Chemical Co. (Ann Arbor, MI, USA). Recombinant human
interleukin (IL)-6 was purchased from R&D Systems (Minneapolis, MN,
USA). N-Acetyl-L-cystein (NAC) was obtained from Sigma-Aldrich (St
Louis, MO, USA). Minimum essential medium (MEM) and penicillin-
streptomycin were obtained from Gibco BRL (Grand Island, NY, USA).
Fetal bovine serum (FBS) was purchased from HyClone (South Logan,
UT, USA). HO-1 polyclonal antibody was a product of Enzo Life Science
(Postfach, Lausen, Switzerland). Primary antibodies against Nrf2, TXN,
protein kinase B (AKT), phospho-AKT, c-Jun N-terminal kinase (JNK),
phospho-JNK, extracellular signal-regulated kinase (ERK), phospho-
ERK, p38, phospho-p38, STAT3, and phospho-STAT3 were products of
Cell Signaling Technology (Beverly, MA, USA). Anti-GAPDH, anti-
Lamin B, and anti-NQO1 were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Anti-rabbit and anti-mouse
horseradish peroxidase-secondary antibody were provided by Thermo
Scientific (Rockford, MD, USA). The ECL chemiluminescent detection
kit was obtained from ELPIS-BIOTECH (Daejeon, Korea). LY294002 was
purchased from TOCRIS (Ellisville, MO, USA). SB203580, SP600125,
and U0126 were the products of Calbiochem (San Diego, CA, USA).
2′,7′-Dichlorofluorescein diacetate (DCF-DA) was obtained from
Invitrogen (Invitrogen, Carlsbad, CA, USA). Hank's balanced salt solu-
tion (HBSS) was purchased from Gibco BRL (Grand Island, NY, USA).
Polyvinylidene difluoride (PVDF) membranes were supplied from
Millipore (Burlington, MS, USA).
2.2. Cell culture
Human CCD 841 CoN colon normal epithelial cells were obtained
from American Type Culture Collection (ATCC, Manassas, VA, USA).
These cells were cultured in MEM supplemented with 10% (v/v) FBS,
100 units/mL penicillin and 100 μg/mL streptomycin at 37 °C in an
incubator with a humidified atmosphere of 95% O2/5% CO2.
2.3. Nuclear and cytoplasmic protein extraction
Cytoplasmic proteins were separated in buffer A [10mM HEPES,
1.5 mM MgCl2, 10mM KCl, 0.5 mM dithiothreitol (DTT), 0.2mM phe-
nylmethylsulfonyl fluoride (PMSF), and 0.1% NP-40]. Nuclear pellets
were washed twice with buffer A with protease inhibitors and then
lysed in buffer C [20mM HEPES, 100% glycerol, 420mM NaCl, 1.5 mM
MgCl2, 0.2mM EDTA, 0.5mM DTT, and 0.2mM PMSF]. Quantification
of protein was performed by the Bradford method according to standard
protocols.
2.4. Western blot analysis
Cells were collected and lysed in ice-cold lysis buffer [20mM Tris-
HCL, 150mM NaCl, 1 mM Na2EDTA, 1mM EGTA, 1% Triton, 2.5 mM
sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, and
1 μg/mL leupeptin] containing protease inhibitors (Cell Signaling
Technology; Danvers, MA, USA). Lysates were centrifuged at 13,000
rpm for 15min at 4 °C. The protein concentration was determined by
using the Bio-Rad Protein Assay (Bio-Rad; Hercules, CA, USA), and
25–30 μg of protein was electrophoresed in SDS-acrylamide gels and
transferred to Immobilon®-P PVDF membrane (EMD Millipore
Cooperation; Billerica, MA, USA) at 100mA for 1 h. The membrane was
blocked in 5% non-fat dry milk solved in 0.05% Tween 20 in PBS
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(PBST) for 1 h. Afterwards, the blots were incubated with the primary
antibody diluted in PBST buffer overnight at 4 °C. After washing, the
blots were incubated with horseradish peroxidase-conjugated sec-
ondary antibody. The immunoblot with protein-antibody complexes
were detected by using an enhanced chemiluminescence detection kit
(ELPIS-BIOTECH; Daejeon, Korea). The band was detected by the
Chemidoc imaging system (CAN ICES-3, Bio-rad).
2.5. Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated from CCD 841 CoN colon normal epithelial
cells using the easy-BLUE method (iNtRON; Burlington, MA, USA) fol-
lowing the manufacturer's instructions. To generate complementary
DNA (cDNA), 1 μg of total RNA was reverse transcribed by using murine
leukemia virus reverse transcriptase (Promega; Madison, WI, USA).
Amplification of genes was performed by PCR analysis using SolgTM 2x
Taq PCR Smart Mix (Solgent; Daejeon, Korea) according to
manufacturer's instructions. The primers used were as follows: GAPDH
(Forward); 5′-AAG GTC GGA AAC GGA TTT-3′, GADPH (Reverse); 5′-
GCA GTG AGG GTC TCT TCT CT-3′, HMOX1 (Forward); 5′-CAG GCA
GAG AAT GCT GAG TTC-3′, HMOX1 (Reverse) 5′-GAT GTT GAG CAG
GAA CGC AGT-3′, NQO1 (Forward); 5′-CAC ACT CCA GCA GAC GCC
CG-3′, NQO1 (Reverse); 5′-TGC CCA AGT GAT GGC CCA CAG-3′, TXN
(Forward); 5′-CAC ACT CCA GCA GAC GCC CG-3′, TXN (Reverse); 5′-
TGC CCA AGT GAT GGC CCA CAG-3′. The amplified transcript level of
each specific gene was normalized to that of GAPDH. The PCR product
was run on 1.5% agarose gel followed by staining of DNA using
RedSafe™ (iNtRON, Burlington, MA, USA). The image analysis was
performed using the Chemidoc imaging system (CAN ICES-3, Bio-rad).
2.6. Immunocytochemistry
CCD 841 CoN cells were plated on the 8-well chamber slides at a
density of 1×104 and treated with 15-keto PGE2 or vehicle alone.
Fig. 1. 15-Keto PGE2 induced expression of
HO-1 in human colon epithelial CCD 841 CoN
cells. (A) CCD 841 CoN cells were treated with
either DMSO or 15-keto PGE2 (20 and 40 μM)
for 24 h. The whole lysates were subjected to
immunoblot analysis for the measurement of
HO-1. GAPDH was used as an equal loading
control for normalization. (B)
Immunofluorescent staining was done for as-
sessing HO-1 expression in the CCD 841 CoN
cells treated with 15-keto PGE2 (40 μM) or ve-
hicle for 12 h. The cells were fixed with 2%
buffered formaldehyde solution and blocked
with 3% BSA. The cells were immunoblotted
with anti-HO-1 primary antibody and a fluor-
ophore-conjugated secondary antibody. DAPI
was applied for staining nucleus before detec-
tion of HO-1 by fluorescence microscopy. (C, D)
CCD 841 CoN cells were treated with 15-keto
PGE2 (40 μM) for the indicated periods. The
mRNA level of antioxidant proteins was de-
termined by RT-PCR (C). The lysates were sub-
jected to immunoblot analysis for measuring the
protein levels of HO-1, TXN, and NQO-1 (D). Bar
graphs show means ± S.E. from at least 3 re-
plicated experiments. *p < 0.05, **p < 0.01,
***p < 0.001.
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Following fixation of cells by incubation in PBS with 2% formaldehyde
at room temperature for 10–15min, the fixed cells were permeabilized
for 5min at room temperature using 0.2% Triton X-100 in PBS. The
cells were blocked with 3% bovine serum albumin (BSA) in PBS con-
taining 0.1% Triton X-100 for 1 h at room temperature and washed with
PBST and then incubated with diluted (1:200) primary antibody for
overnight at 4 °C. After washing with PBST, samples were incubated
with Fluorophore-conjugated secondary antibodies (Alexa fluor® 488)
for another 1 h at room temperature. Samples were washed with 0.05%
PBST containing 3% BSA and then examined under an LSM 700 con-
focal microscope (ZEISS; Oberkochen, Germany) integrated by ZEN
imaging software.
2.7. Transfection
The small interfering RNA (siRNA) of Nrf2 and its negative control
siRNA were purchased from Genolution Pharmaceuticals (Seoul,
Korea). The sequence of human specific Nrf2-siRNA used is as follows:
sense 5′-GGGAGGAGCUAUUAUCCAUUU-3′; antisense 5′-AUGGAUAA
UAGCUCCUCCCUU-3′. Human CCD 841 CoN cells (4× 105/6-well)
were transfected with 20 nM of oligonucleotides using Lipofectamine
RNAiMAX according to manufacturer's instructions (Thermo Fisher
Scientific; Waltham, MA, USA).
2.8. ARE luciferase reporter gene assay
CCD 841 CoN cells were plated at a confluence of 50% density in 6-
well plate and grown in MEM media supplemented with 5% heat-in-
activated horse serum at 37 °C in a humidified atmosphere of 5% CO2/
95% air. The cells were co-transfected with 1 μg of the luciferase re-
porter gene fusion construct (pTi-luciferase), wild-type ARE, and 0.5 μg
of pCMV-β-galactosidase control vector with WelFect-M™ Gold trans-
fection reagent according to the manufacturer's instructions. After 24-h
transfection, the cells were treated with 15-keto PGE2 for additional
12 h and the cell lysis was carried out with the 1x reporter lysis buffer
(Promega; Madison, WI, USA). After mixing the cell extract with a lu-
ciferase substrate (Promega, Madison, WI, USA), the luciferase activity
was measured by the luminometer. The β-galactosidase assay was done
according to the supplier's instructions (Promega β-galactosidase
Enzyme Assay System) for normalizing the luciferase activity.
Fig. 2. 15-Keto PGE2-induced HO-1 expres-
sion mediated by Nrf2. (A) CCD 841 CoN cells
were treated with 15-keto PGE2 (40 μM) for the
indicated time periods. The nuclear fractions
were subjected to immunoblot analysis for the
measurement of Nrf2. Lamin B1 was used as a
nuclear protein marker. Western blot analysis
was conducted at least 3 times and the blot is the
representative one. (B) The effect of 15-keto
PGE2 (40 μM) on the nuclear localization of Nrf2
was determined by immunocytochemical ana-
lysis. (C) CCD 841 CoN cells were co-transfected
with pCMV-β-galactosidase and either the luci-
ferase reporter gene fusion construct (pGL2) or
ARE luciferase reporter gene for 36 h, followed
by treatment with DMSO or 15-keto PGE2
(40 μM) for additional 12 h. The transcriptional
activity of Nrf2 was assessed based on the ARE-
driven luciferase activity. (D) CCD 841 CoN cells
were transfected with siRNA negative control or
siNrf2 for 12 h and exposed to 15-keto PGE2
(40 μM) for another 12 h. The lysates from
transfected cells were subjected to Western blot
analysis. All graphs show the mean ± S.E.
(n= 3). *p < 0.05, **p < 0.01,
***p < 0.001.
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2.9. Measurement of intracellular reactive oxygen species (ROS)
Accumulation of ROS in CCD 841 CoN cells treated with 15-keto
PGE2 was monitored using the fluorescence-generating probe, DCF-DA.
The cells (1× 105/mL) were then washed once with HBSS and treated
with 10mM DCF-DA to assess ROS-mediated oxidation of DCF-DA to
the fluorescent compound DCF. After 30-min incubation at 37 °C, the
cells were examined under a confocal fluorescence microscope set at
488 nm for excitation and 530 nm for emission.
2.10. Statistical analysis
All data are analyzed by means ± S.E. and are based on experi-
ments performed at least in triplicate. Statistical significance was cal-
culated with the Student's t-test and GraphPad Prism 8 (San Diego, CA,
USA) software.
3. Results
3.1. 15-Keto PGE2 upregulates expression of HO-1 in CCD 841 CoN cells
We initially selected non-cytotoxic concentrations of 15-keto-PGE2
in human normal colon epithelial CCD 841 CoN cells by the MTT assay.
The concentrations (20 μM and 40 μM) used in this experiment did not
show any cytotoxic effect up to 24 h. We observed that 15-keto PGE2
(40 μM) induced the expression of HO-1 as determined by Western blot
analysis (Fig. 1A). The induction of HO-1 by 15-keto-PGE2 was also
verified by immunocytochemical analysis (Fig. 1B). To determine
whether 15-keto PGE2 could induce expression of other antioxidant
enzymes such as TXN and NQO1, CCD 841 CoN cells were treated with
this lipid mediator for different periods (3 h, 6 h, 12 h, and 24 h). While
both mRNA and protein expression of HO-1 was upregulated at 6 h and
sustained up to 12 h upon 15-keto PGE2 treatment, the expression of
TXN and NQO1 was not induced (Fig. 1C and D).
3.2. 15-Keto PGE2 stimulates the nuclear translocation and transcriptional
activity of Nrf2
As Nrf2 is the primary transcription factor for regulating the ex-
pression of HO-1, we investigated whether 15-keto PGE2 could affect
the activation of Nrf2. 15-Keto PGE2 induced the nuclear translocation
of Nrf2 which was evident at 3 h after the treatment and gradually
increased up to 12 h (Fig. 2A). This was also observed by im-
munocytochemical analysis (Fig. 2B). In addition, we assessed the
transcriptional activity of Nrf2 by transfecting CCD 841 CoN cells with
an ARE driven-luciferase vector. Treatment of CCD 841 CoN cells with
Fig. 3. The role of AKT in 15-keto PGE2-in-
duced HO-1 expression. (A) Effects of 15-keto
PGE2 on the activity of protein kinases including
AKT, ERK, p38, and JNK. The cells were treated
with 15-keto PGE2 (40 μM) for the indicated
time. (B) Effects of kinase inhibitors on 15-keto
PGE2-induced HO-1 expression. Cells were pre-
incubated for 1 h with LY294002 (10 μM),
U0126 (5 μM), SB203580 (10 μM), or SP600125
(10 μM), followed by 15-keto PGE2 treatment for
12 h. The lysates were subjected to immunoblot
analysis for the measurement of HO-1. (C)
Effects of AKT inhibition on 15-keto PGE2-in-
duced expression of Nrf2 and HO-1. Cells were
treated with 15-keto PGE2 (40 μM) for 12 h in
the absence or presence of LY294002 (10 μM).
The lysates were subjected to immunoblot ana-
lysis for the measurement of Nrf2, HO-1, AKT,
and P-AKT. Data are expressed as the
mean ± S.E. (n = 3). ***p < 0.001.
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15-keto PGE2 significantly enhanced the luciferase intensity in cells
transfected with ARE driven-luciferase vector (Fig. 2C). We further
determined whether 15-keto PGE2-induced Nrf2 activation is re-
sponsible for the induction of HO-1 expression. For this purpose, cells
were transfected with either negative siRNA or Nrf2 siRNA. We ob-
served that the silencing of Nrf2 abolished the 15-keto PGE2-mediated
upregulation of HO-1 (Fig. 2D). This finding suggests that Nrf2 plays an
important role in the induction of HO-1 expression by 15-keto PGE2.
3.3. 15-Keto PGE2-induced Nrf2-HO-1 upregulation is mediated through
AKT activation
Dissociation of the Nrf2-Keap1 complex is stimulated through the
phosphorylation of Nrf2 by distinct upstream kinases. To determine the
upstream signaling events that lead to activation of Nrf2 and
consequent HO-1 expression, we assessed activation of several kinases
including AKT and mitogen-activated protein kinases such as ERK, JNK,
and p38. We found that 15-keto PGE2 induced the phosphorylation of
AKT and ERK1/2 (Fig. 3A). The pharmacological inhibitor of AKT
(LY294002) attenuated the 15-keto PGE2-induced expression of HO-1,
while U0126 (MEK inhibitor), SB203580 (p38 inhibitor) and SP600125
(JNK inhibitor) exerted no inhibitory effect (Fig. 3B). Further, blockade
of AKT activity with LY294002 attenuated accumulation of Nrf2 and
expression of HO-1 (Fig. 3C), suggesting that activation of the Nrf2/HO-
1 axis by 15-keto PGE2 is mediated by AKT .
3.4. 15-Keto PGE2 stimulates the generation of ROS
Although both excess and insufficient ROS impair normal physio-
logic functions, a moderate generation of ROS is necessary for the
Fig. 4. 15-Keto PGE2-induced generation of
ROS. (A) Generation of ROS in CCD 841 CoN
cells treated with 15-keto PGE2 was monitored
using the fluorescence-generating probe DCF-DA.
CCD 841 CoN cells were incubated with 15-keto
PGE2 (40 μM) in the absence or presence of NAC
(5mM) for 12 h. (B, C) CCD 841 CoN cells were
incubated with 15-keto PGE2 (40 μM) in the ab-
sence or presence of NAC (5mM) (B) or DTT
(0.5mM) (C) for 12 h. The expression levels of P-
GSK3β, GSK-3β, Nrf2, Keap1, and HO-1 were
measured by the Western blot analysis. (D) CCD
841 CoN cells were co-transfected with pCMV-β-
galactosidase and either the luciferase reporter
gene fusion construct (pGL2) or ARE luciferase
reporter gene for 36 h, followed by treatment
with DMSO, 15-keto PGE2, 15-keto PGE2 plus
NAC, or NAC alone for 12 h. The transcriptional
activity of Nrf2 was measured by the ARE luci-
ferase reporter assay as described in Methods. Bar
graphs show the mean ± S.E. (n=3).
*p < 0.05, **p < 0.01, ***p < 0.001.
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maintenance of cellular redox balance and homeostasis [24]. Nrf2 is
adaptively activated upon intracellular oxidative stress. When we ex-
amined the level of ROS in CCD 841 CoN cells treated with 15-keto
PGE2 using DCF-DA staining, there was a generation of intracellular
ROS, which was abolished by a general antioxidant NAC (Fig. 4A). NAC
treatment also attenuated the accumulation of Nrf2 and expression of
HO-1 (Fig. 4B). GSK3β, a downstream kinase of AKT, has been known
to stimulate Nrf2 degradation, independently of Keap1 signaling [25].
GSK3β undergoes inactivation through phosphorylation at Ser9. 15-
Keto PGE2 induced phosphorylation of GSK3βSer9, which was abolished
by NAC (Fig. 4B). Similar results were achieved with another reducing
agent DTT (Fig. 4C). Moreover, 15-keto PGE2-induced transcriptional
activity of Nrf2 was also attenuated by NAC (Fig. 4D). These findings
suggest that ROS production induced by 15-keto PGE2 contributes to
the activation of Nrf2 and the expression of HO-1 through activation of
the GSK3β pathway.
3.5. The α,β-unsaturated carbonyl group of 15-keto PGE2 is critical for
Nrf2 activation and subsequent HO-1 expression
15-Keto-PGE2 has an α,β-unsaturated carbonyl moiety which is
capable of interacting with nucleophilic cellular proteins [26]. The
biological function of many electrophilic compounds has been
attributable to their α,β-unsaturated carbonyl groups [27,28]. 15-Keto
PGE2 is converted by prostaglandin reductase 2 (PTGR2) to 13,14-di-
hydro-15-keto PGE2 lacking an electrophilic α,β-unsaturated carbonyl
group [29] (Fig. 5A). As shown in Fig. 5B, 13,14-dihydro-15-keto PGE2
failed to generate ROS, while 15-keto-PGE2 did (Fig. 5B). Further, the
accumulation of Nrf2 and expression of HO-1 were less pronounced in
the cells treated with 13,14-dihydro-15-keto PGE2 compared to those
treated with 15-keto PGE2 (Fig. 5C). These findings indicate that the
α,β-unsaturated carbonyl group of 15-keto PGE2 is critical for Nrf2
activation and subsequent HO-1 expression.
3.6. 15-Keto PGE2-induced HO-1 expression may contribute to protecting
cells against oxidative cell death and inflammation
Induction of HO-1 has been known to protect the cells against oxi-
dative or inflammatory stress [30]. Treatment of CCD 841 CoN cells for
6 h with hydrogen peroxide (H2O2) induced apoptosis as evidenced by
the cleavage of poly(ADP-ribose) polymerase 1 (PARP-1) and down-
regulation of Bcl-2 phosphorylation (Fig. 6A). The pre-treatment with 15-
keto PGE2 for 6 h attenuated both pro-apoptotic events in H2O2-treated
cells (Fig. 6A). The transcription factor STAT3 plays a pivotal role in
inflammation and inflammation-associated carcinogenesis [31]. Phos-
phorylation at the Tyr705 is essential for the activation of STAT3. 15-Keto
Fig. 5. The importance of α,β-unsaturated
carbonyl group for 15-keto PGE2-induced
Nrf2 activation and subsequent HO-1 ex-
pression. (A) 15-Keto PGE2 possesses the α,β-
unsaturated carbonyl moiety which has a che-
mically reactive carbon center, whereas 13,14-
dihydro-15-keto PGE2 lacks this electrophilic
moiety. (B) The comparison of ROS generation
in the cells treated with DMSO, 15-keto-PGE2
(40 μM) or 13,14-dihydro-15-keto PGE2
(40 μM). (C) The effect of 15-keto PGE2 (40 μM)
and 13,14-dihydro-15-keto PGE2 (40 μM) on
nuclear localization of Nrf2 and expression of
HO-1. The expression of Nrf2 and HO-1 was
determined by Western blot analysis. GAPDH
and Lamin B were used as an equal loading
control and a nuclear protein marker, respec-
tively. *p < 0.05, **p < 0.01.
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PGE2 inhibited the STAT3 phosphorylation induced by the pro-in-
flammatory cytokine IL-6 in CCD 841 CoN cells (Fig. 6B). These findings
suggest that 15-keto PGE2-induced expression of HO-1 may contribute to
protecting cells against oxidative cell death and inflammation.
4. Discussion
Inflammatory disorders including inflammation-associated cancer
are largely driven by the generation of a proinflammatory PGE2. This
lipid mediator governs inflammatory responses by eliciting vasodila-
tation and enhancing vascular permeability, thereby mediating the in-
flux of leukocytes [32,33]. In many solid tumors, PGE2 is often over-
produced [34-36] and is tightly linked to chemoresistance [37].
Although suppression of PGE2 generation by COX-2 selective inhibitors
could be a therapeutic option in the management of inflammation-as-
sociated cancer, this may also inhibit the production of certain down-
stream lipid mediators which may jeopardize the resolution of in-
flammation [38,39].
Recently, 15-keto PGE2 is considered as a novel lipid mediator
possessing anti-inflammatory properties. We observed that 15-keto
PGE2 induces HO-1 expression through Nrf2 activation, which con-
tributes to its anti-inflammatory and anti-oxidative effects.
Consistently, Chen et al. have also reported that 15-keto-PGE2 induces
HO-1 via Nrf2 activation in macrophages [15]. Nrf2-mediated HO-1
induction contribute to adaptive survival response [40]. Upon activa-
tion of Nrf2, upregulation of HO-1 expression not only mediates an anti-
oxidant reaction but also facilitates anti-inflammatory, antiapoptotic
and antiproliferative events [41]. In our present study, 15-keto PGE2
suppressed the H2O2-induced apoptosis and phosphorylation of STAT3
induced by IL-6. Therefore, anti-inflammatory and cytoprotective ef-
fects of 15-keto PGE2 may be largely mediated through activation of
Nrf2-HO-1 signaling.
Nrf2 plays a pivotal role not only in the cellular defense against
oxidative stress but also in protection against inflammatory disorders
[19]. Mice deficient in Nrf2 developed more severe colitis upon treat-
ment with DSS than wild type mice [42]. Likewise, the levels of pro-
inflammatory mediators, such as COX-2, were remarkably increased in
the colonic tissues of Nrf2−/− mice as compared to their wild-type
counterparts [42]. In addition, Nrf2 is a critical suppressor of colon
cancer progression as well as inflammation. Nrf2 knockout mice were
more susceptible to the formation of colorectal cancer than wild-type
mice treated with the carcinogen azoxymethane plus DSS [43]. No-
tably, Nrf2 activation exhibited a preventive effect on the initiation of
Fig. 6. Protective effects of 15-keto PGE2 on oxidative stress-induced
apoptosis and IL-6-induced activation of STAT3 signaling. (A) H2O2
(300 μM) was treated to CCD 841 CoN cells in the absence or presence of 15-
keto PGE2 (40 μM) for 6 h. Cleavage of PARP-1 and phosphorylation of Bcl-2
were evaluated by Western blot analysis. (B) The pro-inflammatory cytokine IL-
6 was treated to CCD 841 CoN cells for 3 h in the absence or presence of 15-keto
PGE2 (40 μM) for 12 h. Nrf2, HO-1, phosphorylated STAT3, and STAT3 were
detected by Western blot analysis.
Fig. 7. A proposed scheme for activation of
Nrf2 by 15-keto PGE2. 15-Keto PGE2 may sta-
bilize and stimulate accumulation of Nrf2 by
blocking its degradation. In one way, it induces
the generation of intracellular ROS and sub-
sequent activation of AKT. AKT triggers phos-
phorylation of GSK3β and results in deactivation
of this kinase, thereby attenuating SCF/β-TrCP-
mediated Nrf2 degradation. In another way, 15-
keto PGE2 reacts with the cysteine residue of
Keap1 and blocks the Keap1-dependent de-
gradation of Nrf2. The stabilized Nrf2 translo-
cates into the nucleus and regulates the expres-
sion of HO-1.
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pulmonary cancer [44], although it can be hijacked by cancer cells,
leading to stimulation of cancer progression [44,45]. It appears that
Nrf2 inhibits the initiation of carcinogenesis, but may function as an
oncogenic protein once cells are transformed to (pre)cancerous ones
[46,47].
15-Keto PGE2 has an α,β-unsaturated carbonyl moiety and is me-
tabolized to non-electrophilic 13,14-dihydro-15-keto PGE2 by PTGR
[29]. We have observed that the α,β-unsaturated carbonyl moiety of
15-keto PGE2 plays an important role in activating Nrf2 as 13,14-di-
hydro-15-keto PGE2 was inactive in this regard. 15-Keto PGE2 cova-
lently reacts with free cysteine residues of proteins involved in the
regulation of the intracellular signaling pathways. Our recent study
reveals a reaction of the α,β unsaturated carbonyl group of 15-keto
PGE2 with the Cys259 residue present in STAT3 [18], which accounts
for its anticarcinogenic response. The canonical activation of Nrf2 is
carried out by oxidation of cysteine residues present in the inhibitory
protein Keap1 [48] including Cys151, 273 and 288 [49]. The cysteine
modification of Keap1 by electrophiles either changes its conformation
or deactivates the Keap1-ubiquitin E3 ligase complex, resulting in a
dissociation of Nrf2 from Keap1 or blockade of ubiquitination-related
degradation of Nrf2, respectively. It has recently been reported that 15-
keto PGE2 covalently binds to the Cys288 residue of Keap1, which may
account for its inhibition of pro-inflammatory cytokine production and
induction of antioxidant gene expression in murine macrophages [15].
Consistent with the above study, our data on the attenuation of 15-keto
PGE2-induced Nrf2 accumulation and HO-1 expression by NAC and DTT
suggest the Keap1 cysteine thiol modification as an underlying me-
chanism (Fig. 7). Another electrophilic lipid mediator, 15-deoxy-Δ12,14-
prostaglandin J2 (15d-PGJ2), modifies cysteine residues of target pro-
teins such as phosphatase and tensin homolog (PTEN) and carries out
distinct biological functions [50]. 15d-PGJ2 induces the expression of
HO-1 via activation of Nrf2 signaling in macrophages, which is asso-
ciated with efferocytosis, a key event in the resolution of inflammation
[51].
Activation of Nrf2 is regulated by AKT/GSK-3β signaling [52,53].
GSK-3β, downstream of AKT signaling, has been known to phosphor-
ylate a group of Ser residues in the Neh6 domain of mouse Nrf2 and
promotes its degradation by E3 ubiquitin ligase SCF/β-TrCP [25]. AKT
phosphorylates GSK-3β, thereby inactivating the latter kinase, which
contributes to Nrf2 activation [53]. Based on this finding, phosphor-
ylation of AKT and GSK3β by 15-keto PGE2 likely suppresses Nrf2 de-
gradation mediated by SCF/β-TrCP even without affecting Keap1
(Fig. 7). It has been reported that hydrogen peroxide generated by 15d-
PGJ2 oxidizes and inactivates PTEN, leading to activation of AKT [50].
In line with this speculation, one plausible mechanism by which 15-
keto PGE2 activates AKT signaling may involve oxidative inactivation of
the PTEN, a negative regulator of PI3K-AKT, through the generation of
ROS.
It has been reported that the silencing of PTGR2 or treatment with
15-keto-PGE2 increases ROS production, which leads to pancreatic
cancer cell death [17]. In this study, 15-keto PGE2 reduces the level of
GSH, a first-line of cellular antioxidant defense, and expression of solute
carrier family 7 member 11 and cystathionine γ-lyase which are in-
volved in the production of cysteine and subunit of the cystine/gluta-
mate antiporter [17]. Based on these findings, 15-keto PGE2-induced
generation ROS may occur as a consequence of a low level of GSH in
colon normal epithelial cells.
In conclusion, 15-keto PGE2 stimulates the Nrf2-HO-1 axis through
the generation of ROS in normal colon epithelial cells, which con-
tributes to the potential role of this lipid mediator in preventing cancer
development associated with oxidative stress and inflammatory tissue
damage.
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